Video

CDK4 Inhibition With Palbociclib in MCL

Selina Chen-Kiang, PhD, professor of pathology and immunology, Weill Cornell Medicine, discusses CDK4 inhibition with palbociclib (Ibrance) in mantle cell lymphoma.

Selina Chen-Kiang, PhD, professor of pathology and immunology, Weill Cornell Medicine, discusses CDK4 inhibition with palbociclib (Ibrance) in mantle cell lymphoma (MCL).

The CDK4/6 inhibitor palbociclib has been shown to overcome ibrutinib (Imbruvica) resistance in primary human samples and MCL cell lines with the mutated BTKC481S protein. Targeting CDK4 is a rational approach in MCL, says Chen-Kiang, as dysregulation of CDK4 and cyclin D1 underlies unrestrained proliferation of MCL cells.

In a phase I clinical trial of 6 patients, palbociclib was administered to patients with MCL for 12 days, and bortezomib (Velcade) was given in prolonged early G1 arrest after synchronous S phase reentry. One patient progressed and 1 patient has been in complete remission for 6 years, suggesting that CDK4 inhibition reprograms MCL for therapy vulnerability. The follow-up clinical trial combined palbociclib together with ibrutinib. The combination looked durable with low toxicity, and induced impressive complete responses by preliminary analysis, says Chen-Kiang.

Related Videos
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD
Sheldon M. Feldman, MD
Laura J. Chambers, DO
Thomas Westbrook, MD
Massimo Cristofanilli, MD, attending physician, NewYork-Presbyterian Hospital; professor, medicine, Weill Cornell Medical College, Cornell University
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
Ajay K. Nooka, MD, MPH, FACP